Find a study
Browse recruiting studies near you — free to check, always your choice.
257 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- DepressionAnxiety
Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease
Testing whether therapy sessions can help teens and young adults with sickle cell cope with
📍 Children's Hospital Los Angeles · Los Angeles, CA · Get directions →
The current study seeks to build on previous research that demonstrates the efficacy of Acceptance and Commitment Therapy in combating stigma by investigating the feasibility and acceptability of a protocol to support Black adolescents and young adults in coping with race related stress. The study will consist of a small, purposeful, non-randomized sample (N = 30) of clients enrolled into a 10-session Acceptance and Commitment Therapy group.
- Depression
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Testing lumateperone added to usual care for major depressive disorder
📍 University of Alabama at Birmingham · Huntsville, AL · +24 more US sites · Get directions →
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
- Depression
The Role of mGluR5 in CBT-I
Testing how a brain receptor may affect CBT-I for insomnia in people with depression
📍 Stony Brook University: Dept of Psychiatry · Stony Brook, NY · Get directions →
This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.
- Depression
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Testing azetukalner compared with a placebo for adults with major depression
📍 Harmonex Neuroscience Research · Dothan, AL · +33 more US sites · Get directions →
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
- Depression
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
Testing brain scan and EEG measures to predict response to depression treatment
📍 Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 · Austin, TX · Get directions →
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.
- Depression
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
Testing whether a brain receptor change affects ketamine’s effect on depression
📍 Yale University · New Haven, CT · Get directions →
The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.
- Obesity / overweight
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
Testing the safety and side effects of injections of MBX 4291 in adults with obesity
📍 MBX Biosciences Investigational Site · Doral, FL · +3 more US sites · Get directions →
The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.
- Depression
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Testing azetukalner versus a placebo for bipolar depression in adults
📍 Noble Clinical Research · Tucson, AZ · +27 more US sites · Get directions →
X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).
- Obesity / overweight
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
Testing how blocking blood sugar to urine affects fat inflammation and blood vessel function in
📍 Vanderbilt University Medical Center · Nashville, TN · Get directions →
Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened chronic inflammation arising from adipose tissue. There are no current targeted therapies to prevent or reverse the chronic inflammation of obesity, and a better understanding of these inflammatory pathways in humans is key to future therapeutic interventions.
- Multiple sclerosis (MS)
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Testing remibrutinib in people with relapsing multiple sclerosis who switch from ocrelizumab versus
📍 Perseverance Research Center · Scottsdale, AZ · +39 more US sites · Get directions →
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
- Depression
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
Testing how dimethyltryptamine affects safety and depression symptoms
📍 Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, · West Haven, CT · Get directions →
The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects.
- Obesity / overweight
A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
Testing how a new medicine affects safety and body processing in people with obesity
📍 Medpace Clinical Pharmacology Unit · Cincinnati, OH · Get directions →
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single and multiple ascending doses in healthy and obese participants.
- Type 2 diabetesHigh cholesterol
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Testing whether a daily cholesterol medicine, alone or with ezetimibe, works on top of standard
📍 Clinical Research Institute of Arizona · Sun City West, AZ · +19 more US sites · Get directions →
This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and/or Type 2 Diabetes Mellitus.
- Depression
Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures
Testing how feasible it is to prescribe antidepressants after fragility fractures in adults 50 and
📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →
The goal of this pilot study is to learn about the feasibility about prescribing anti-depressants at discharge in patients aged 50 years and older with a lower extremity fragility fracture. The main questions it aims to answer are: * What are the obstacles to enrolling patients and prescribing anti-depressants among older adults?
- Multiple sclerosis (MS)
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
Testing the safety and effects on disease and immune cells of one dose of YTB323 in people with
📍 Novartis Investigative Site · Darlinghurst, New South Wales · Get directions →
This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.
- Depression
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
Testing whether a low-dose ketamine IV treatment is safe and workable in the ER for people with
📍 University of Kansas Strawberry Hill Campus · Kansas City, KS · +1 more US site · Get directions →
There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.
- Multiple sclerosis (MS)
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Testing a modified ublituximab treatment for relapsing multiple sclerosis
📍 TG Therapeutics Investigational Trial Site · Birmingham, AL · +34 more US sites · Get directions →
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.
- Obesity / overweight
Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients
Testing a program with weight loss help and smoking quitting for adults before bariatric surgery
📍 Yale University · New Haven, CT · Get directions →
The purpose of this research study is to develop and pilot a multiple health behavior change intervention for weight loss and smoking cessation using medication (Naltrexone + Bupropion) and behavior therapy in adults seeking bariatric surgery.
- Multiple sclerosis (MS)
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Testing safety of a new immune cell therapy in adults with multiple sclerosis
📍 Research Site · Tucson, AZ · +8 more US sites · Get directions →
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
- Multiple sclerosis (MS)
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Testing safety of a twice-yearly medicine for early relapsing MS
📍 Northwestern Memorial Hospital · Chicago, IL · Get directions →
In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.
- Obesity / overweight
A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Testing the safety and how a single dose works in healthy people with obesity
📍 Fortrea Clinical Research Unit · Madison, WI · Get directions →
The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.
- Obesity / overweight
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
Testing a 52-week medicine versus placebo in adults with obstructive sleep apnea on CPAP
📍 Valley Clinical Trials · Northridge, CA · +12 more US sites · Get directions →
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.
- Depression
Dopaminergic Therapy for Anhedonia - 2
Testing an 8-week treatment using L-DOPA for depression with low pleasure and high inflammation
📍 Emory University Hospital · Atlanta, GA · Get directions →
The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks.
- Obesity / overweight
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Testing how fasting and briefly stopping GLP-1 medicines changes stomach food
📍 Altasciences Clinical LA, Inc. · Cypress, CA · Get directions →
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.
- Depression
Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression
Testing how one-time exercise and ibuprofen affect bipolar depression symptoms
📍 Laureate Institute for Brain Research · Tulsa, OK · Get directions →
This is a 2x2, within-subjects, cross-over trial to test the anti-depressant effects of acute exercise in 20 participants with bipolar depression. Participants will complete four experimental sessions, two with an exercise challenge and two with a resting control condition in a counterbalanced order.
- Obesity / overweight
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
Testing whether obesity genes predict weight loss from a diet and a medicine
📍 Columbia University Medical Center · New York, NY · Get directions →
The goal of this clinical trial is to understand if genetic variations are associated with the amount of weight loss with diet and while taking an FDA-approved medication for weight loss. The main question\[s\] it aims to answer are: * In Aim One, the investigators propose to rigorously test the hypothesis that presence of the Taq1A A1+ polymorphism is associated with greater weight loss with NB compared with the A1- genotype.
- DepressionAnxiety
ACT for Individuals With MNCD and Their Care Partners
Testing acceptance commitment therapy for depression and anxiety in dementia
📍 Texas Tech University Plaza Building · Lubbock, TX · Get directions →
This project aims to implement and evaluate a dyadic intervention (i.e., acceptance commitment therapy) for persons with AD/ADRD and their care partners. We hypothesize the intervention will be feasible, acceptable, and show preliminary efficacy of the dyadic interveniotns.
- Obesity / overweight
Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance
Testing how added dietary fiber and metformin, alone or together, affect insulin resistance and
📍 University of Alberta · Edmonton, Alberta · Get directions →
This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance \[IR\]), inflammation and BMI in adolescents with obesity and IR, and to assess the relationship between therapeutic intervention(s) and changes in gut microbiome composition and function. Since MET and FIBER have been shown to reduce weight and increase insulin sensitivity through distinct but overlapping mechanisms of action, our central hypothesis is that the combination of FIBER + MET will have a synergistic effect and be more effective than FIBER or MET alone in improving metabolic function (IR) and reducing BMI and inflammation in adolescents with obesity, IR and family history (FM) of T2DM.
- Obesity / overweight
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Testing a weekly injection in people with obesity and sleep apnea to lose weight and improve sleep
📍 Dignity Health, Mercy Gilbert · Gilbert, AZ · +19 more US sites · Get directions →
This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweight
Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes
Measuring body signals linked to heart and metabolic risk in people with type 1 diabetes and obesity
📍 Yale Pediatric Diabetes Research · New Haven, CT · Get directions →
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events.
- Depression
RCT of Psilocybin-assisted CBT for Depression
Testing psilocybin with cognitive-behavioral therapy for depression
📍 UCLA Semel Institute · Los Angeles, CA · Get directions →
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) examine the clinical benefit of psilocybin as an adjunct to cognitive-behavioral therapy (CBT) for major depressive disorder. This study is a randomized, two-arm, fixed dose trial that will test the feasibility, acceptability, and participant and therapist adherence to PA-CBT.
- Obesity / overweight
Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery
Testing medicines plus lifestyle counseling to manage weight regain after bariatric surgery
📍 University of California Irvine Medical Center · Orange, CA · Get directions →
This is a randomized controlled trial employing a Sequential Multiple Assignment Randomized Trial (SMART) design to test whether pharmacotherapy, in conjunction with lifestyle counseling, can reverse weight regain after bariatric surgery.
- Obesity / overweight
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Testing a weekly under-the-skin injection to see effects on weight and diabetes markers
📍 Kailera Clinical Site · Cullman, AL · +34 more US sites · Get directions →
The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
- Depression
Identifying and Treating Depression in the Orthopaedic Trauma Population
Testing how orthopedic trauma teams can screen for depression and treat it with medication
📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →
The goal of this trial is to pilot a way for orthopaedic surgeons to safely screen for depression and provide treatment for depression with medication. The main questions it aims to answer are: 1.
- Obesity / overweight
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
Testing the effects of a skin injection in adults with obesity, including side effects and how the
📍 CenExel ACT- Anaheim Clinical Trials /ID# 283200 · Anaheim, CA · +1 more US site · Get directions →
This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
- Multiple sclerosis (MS)
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Testing the safety and effects of KITE-363 in people with multiple sclerosis
📍 Stanford Neuroscience Health Center · Palo Alto, CA · +3 more US sites · Get directions →
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases.
- Multiple sclerosis (MS)
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Testing whether combining a walking medication with physical therapy improves mobility in people
📍 MGH Institute of Health Professions · Boston, MA · Get directions →
The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?
- Multiple sclerosis (MS)
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
Testing a CD19 CAR-T cell treatment for progressive multiple sclerosis
📍 Stanford Multiple Sclerosis Center · Palo Alto, CA · Get directions →
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
- Obesity / overweight
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Testing a weekly under-the-skin medicine to help adults with obesity lose weight
📍 South Broward Research LLC · Miramar, FL · +21 more US sites · Get directions →
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweightType 2 diabetes
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Testing different doses of a medicine for weight loss in people with obesity or overweight and type
📍 Lakeview Clinical Research · Guntersville, AL · +33 more US sites · Get directions →
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).
- Depression
Psilocybin for Treatment-Resistant Depression in Autism
Testing psilocybin plus talk therapy for depression in autistic adults
📍 Centre for Addiction and Mental Health · Toronto, Ontario · Get directions →
We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD). In this study, 20 participants (intellectually able and fluent-speech adults) with autism and co-occurring TRD will receive around 20 hours of manualized psychotherapy that has previously been used with psilocybin (Agin-Liebes et al., 2020).
- Obesity / overweightHigh blood pressure
A Study of LY3971297 in Healthy Participants
Testing side effects and how the body processes an injection in healthy and obese people with high
📍 CenExel ACT · Anaheim, CA · +2 more US sites · Get directions →
The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it.
- Obesity / overweight
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
Testing how a skin shot medicine affects safety and body processing in adults with overweight or
📍 Parexel International-EPCU Baltimore · Baltimore, MD · Get directions →
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity.
- DepressionAnxiety
Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome
Studying how gut bacteria in pregnant people relates to depression and anxiety
📍 Sunnybrook Health Science Center · Toronto, Ontario · Get directions →
Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies.
- DepressionAnxiety
Nebulized Ketamine for the Treatment of Major Depressive Disorder
Testing a breathing mist of ketamine to reduce symptoms of major depression
📍 Maimonides Medical Center · Brooklyn, NY · Get directions →
This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
- Obesity / overweight
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Testing whether setmelanotide improves weight loss, hunger, and life quality in children and adults
📍 University of Alabama · Birmingham, AL · +7 more US sites · Get directions →
This is a sub-study of Study RM-493-040 (NCT05774756). The goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with congenital Hypothalamic Obesity (cHO).
- Obesity / overweight
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
Testing the safety and body processing of an oral medicine in overweight adults
📍 ProSciento, INC · Chula Vista, CA · Get directions →
Randomized, Placebo-controlled Study to determine the safety and tolerability of multiple oral doses of TIX100 administered daily for 28 days to otherwise healthy overweight/obese subjects.
- Obesity / overweight
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
Testing a skin patch delivery of semaglutide versus a shot in people with obesity
📍 Celerion Clinical Research · Tempe, AZ · Get directions →
VX-201-101 is a first-in-human Phase 1 clinical study evaluating VX-201, a needle-free microneedle (MN) array patch (MAP) that delivers semaglutide through the skin as an alternative to subcutaneous (SC) injection.
- Depression
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Testing azetukalner against a placebo for major depression in adults
📍 IMA Clinical Research Phoenix · Phoenix, AZ · +39 more US sites · Get directions →
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
- Obesity / overweightType 2 diabetes
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
Testing a medicine to see its safety and weight-loss effects in adults with obesity or overweight
📍 CenExel Anaheim Clinical Trials · Anaheim, CA · +39 more US sites · Get directions →
The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type 2 diabetes lose weight. Being overweight or obese means carrying too much body weight.
- Depression
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Testing a deuterated psilocin-related medicine for major depression
📍 UAB Psychiatry and Behavioral Neurology · Birmingham, AL · +32 more US sites · Get directions →
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/
- Obesity / overweight
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Testing safety and effectiveness of weight-loss medicines for kids with obesity
📍 Carey Chronis MD Pediatric, Infant and Adolescent Medicine · Ventura, CA · +15 more US sites · Get directions →
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
- Multiple sclerosis (MS)
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Testing a drug called orelabrutinib versus placebo in people with PPMS
📍 Arizona Neuroscience Research, LLC · Pheonix, AZ · +12 more US sites · Get directions →
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.
- Obesity / overweight
Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.
Testing if an IV medicine during bariatric surgery reduces pain and inflammation in adults with
📍 Hospital de Especialidades Centro Medico Nacional Siglo XXI · Mexico City, Mexico City · Get directions →
The goal of this randomized clinical trial is to find out whether giving an intravenous lidocaine + dexmedetomidine combination (LIDEX) during laparoscopic bariatric surgery can lower post-operative pain, inflammation, and oxidative stress in adults with obesity. The main questions it aims to answer are: * Pain control: Does LIDEX reduce pain 24 hours after surgery, as measured with the International Pain Outcomes Questionnaire (IPOQ)?
- Depression
DBS for Depression
Testing whether deep brain stimulation is safe and feasible for severe depression that hasn’t
📍 Zucker Hillside Hospital · Queens, NY · Get directions →
The goal of this clinical trial is to demonstrate the feasibility and safety of deep brain stimulation in treatment resistant depression. The main questions it aims to answer are: * Is deep brain stimulation effective in treating treatment resistant depression?
- Obesity / overweight
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Testing eloralintide in people with sleep apnea and obesity
📍 Cullman Clinical Trials · Cullman, AL · +22 more US sites · Get directions →
The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2.
- Obesity / overweightHigh blood pressure
Impact GLP-1 Agonists Following Bariatric
Testing whether GLP-1 medicines after bariatric surgery affect weight and blood sugar
📍 University of Missouri Hospital · Columbia, MO · Get directions →
Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.
- Depression
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Testing brenipatide to see if it delays return of major depression symptoms
📍 Accellacare - Moorpark · Moorpark, CA · +31 more US sites · Get directions →
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into three periods as follows: a screening period that will last approximately 1 month, a treatment period that will last a minimum of 12 months, and the follow up period that will last approximately 2 months.
- Obesity / overweight
DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity
Comparing HIV treatment medicines to see how they affect weight in people with obesity
📍 Hospital de infectología, Centro Médico Nacional La Raza · Mexico City, · Get directions →
Background:Historically, HIV infection was associated with significant weight loss. However, weight gain is now commonly observed after initiating antiretroviral therapy (ART), particularly in individuals underweight at baseline.
- DepressionAnxiety
Creatine for Depressed Male and Female Methamphetamine Users
Testing whether creatine helps depression and anxiety in people who use meth
📍 Montana State University College of Nursing (Missoula campus) · Missoula, MT · Get directions →
* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression
- Showing the first 60 of 257. Add filters or a location to narrow down.